Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine -- Ignore unavailable to you. Want to Upgrade?

To: andy harrison who wrote (186)	12/26/1997 9:56:00 AM
From: Don W Stone	Respond to of 507

Andy ; Very good positive thinking post. And than there is DTaP that could go to market in the U.S. very soon. Conjugate Vaccines in development: GBS (GRoup B Strep) vaccine in Phase II studies with a Phase III clinical trial in the planning stage. What is being said is that this vaccine could be administered to all women of child bearing age. Now that is a big market. Several Meningitis vaccines in Phase I/II clinical trials. These could become part of the infant series of vaccines. Another very big market. And the sequel to DTaP; The Combination Vaccines: DTaP-IPV, Approved and in use in Europe. Possible approval in U.S. within the year. DTaP-IPV-Hib, Approved in Europe. Unlike the competition, NVX has experienced no interference amonge the individual vaccines in their combination vaccines. Down the road this will decide who gets what percent of this enormous market. NVX just could end out with the lions share. That's my take. Meanwhile the post marketing studies for CERTIVA just get better and better. :-}. NVX will indeed get their share of the DTaP market and the analyst forecast for earnings as are out there now are only based on that fact and FDA approval by the beginning of '98. Actually the potential is there to blow those numbers away. After all CERTIVA will indeed be the BEST and SAFEST DTaP vaccine on the market. We'll see. :-}, ;--}. :-}.